内科理论与实践››2023,Vol. 18››Issue (01): 16-17.doi:10.16138/j.1673-6087.2023.01.005
中华医学会内分泌学分会
收稿日期:2023-01-15出版日期:2023-01-30发布日期:2023-02-13基金资助:
Chinese Society of Endocrinology
Received:2023-01-15Online:2023-01-30Published:2023-02-13| [1] | Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review[J]. Endocrinology, 163(1): bqab203. |
| [2] | 国务院联防联控机制综合组. 关于印发新型冠状病毒感染防控方案(第十版)的通知[EB/OL]. 2023. http://www.gov.cn/xinwen/202301/07/content_5735448.htm. |
| [3] | 宁光. 糖皮质激素类药物临床应用指导原则[J]. 中华内分泌代谢杂志, 2012, 28(2):171-202. |
| [4] | Arlt W, Baldeweg SE, Pearce SH, et al. L. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 183(1): G25-G32. doi:10.1530/EJE-20-0361URL |
| [5] | 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736. |
| [6] | Tzoulis P, Waung JA, Bagkeris E, et al. Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(6): 1637-1648. doi:10.1210/clinem/dgab107pmid:33624101 |
| [7] | Tzoulis P, Grossman AB, Baldeweg SE, et al. Management of endocrine disease: dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management[J]. Eur J Endocrinol, 2021, 185(4): R103-R111. doi:10.1530/EJE-21-0281URL |
| [8] | Atila C, Sailer CO, Bassetti S, et al. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls[J]. Eur J Endocrinol, 2021, 184(3): 409-418. doi:10.1530/EJE-20-1374pmid:33449918 |
| [9] | 中华医学会内分泌学分会. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 737-750. |
| [10] | Raghavan D, Tan AR, Story ES, et al. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic[J]. Endocr Relat Cancer, 2020, 27(9): R357-R374. doi:10.1530/ERC-20-0229URL |
| [11] | National Institute of Health. Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications[EB/OL]. 2022. https://www.covid19tre-atmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/. |
| [12] | Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19[J]. Science, 2021, 374(6575): 1586-1593. doi:10.1126/science.abl4784URL |
| [1] | 中华医学会内分泌学分会.老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 10-12. |
| [2] | 中华医学会内分泌学分会.甲状腺功能异常新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 13-15. |
| [3] | 中华医学会内分泌学分会.垂体疾病新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 18-21. |
| [4] | 中华医学会内分泌学分会.骨质疏松症新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 22-24. |
| [5] | 中华医学会内分泌学分会.尿崩症患者新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 25-27. |
| [6] | 中华医学会内分泌学分会.新型冠状病毒肺炎疫情下肾上腺疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 139-142. |
| [7] | 胡哲, 陈歆, 罗芳秀, 初少莉, 王继光.肾上腺醛固酮和皮质醇共分泌瘤一例报告[J]. 诊断学理论与实践, 2020, 19(05): 525-527. |
| [8] | 王春花, 祁爽, 王敏.原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530. |
| [9] | 蒋怡然, 王卫庆.原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020, 19(05): 445-449. |
| [10] | 陈歆, 程艾邦, 许建忠, 李燕, 王继光.中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453. |
| [11] | 中国高血压联盟.高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459. |
| [12] | 程艾邦, 李明轩, 陈波, 曹晟, 蒋塨豪, 许建忠, 李燕, 王继光.化学发光免疫分析法检测血浆肾素、醛固酮在原发性醛固酮增多症诊断中的价值[J]. 诊断学理论与实践, 2020, 19(05): 474-480. |
| [13] | 康健捷, 苏佩珣, 邓兵梅, 杨红军, 王卓才.肾上腺腺瘤型原发性醛固酮增多症并发横纹肌溶解症一例[J]. 诊断学理论与实践, 2019, 18(05): 583-584. |
| [14] | 林纬, 陈刚,.妊娠合并库欣综合征的现状与对策[J]. 内科理论与实践, 2019, 14(03): 144-148. |
| [15] | 蒋怡然, 王卫庆,.中国原发性醛固酮增多症诊治专家共识解读[J]. 诊断学理论与实践, 2016, 15(04): 350-353. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
